Hims & Hers Health (HIMS) Stock Price, News & Analysis

Company Overview

Hims & Hers Health, Inc. is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them. The company also offers branded and generic treatments, along with subscription-based services in certain categories.

The Hims brand launched in 2017, followed by Hers in 2018, initially focusing on products and care for men and women before expanding into broader virtual healthcare services. Hims & Hers Health became a publicly traded company in 2021 through a business combination with a special purpose acquisition company. The company is headquartered in San Francisco and primarily serves customers in the United States, with operations also extended to select international markets. Andrew Dudum, a co-founder of the company, serves as chief executive officer.

Key Stats

• Today's Range: $26.68 to $28.75
• 50-Day Range: $27.44 to $33.67
• 52-Week Range: $13.74 to $48.34
• Volume: 10.84 million shs
• Average Volume: 9.80 million shs
• Market Capitalization: $6.44 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.43
• Consensus Rating: Hold

Hims & Hers Health Stock Analysis - MarketRank™

Hims & Hers Health scored higher than 55% of companies evaluated by MarketBeat, and ranked 375th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 11 hold ratings, and 1 sell rating.

Upside Potential

Hims & Hers Health has a consensus price target of $32.43, representing about 17.6% upside from its current price of $27.59.

Amount of Analyst Coverage

Hims & Hers Health has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hims & Hers Health are expected to grow in the coming year, from ($0.16) to $0.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hims & Hers Health is -43.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hims & Hers Health is -43.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hims & Hers Health has a P/B Ratio of 11.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.97% of the float of Hims & Hers Health has been sold short.

Short Interest Ratio / Days to Cover

Hims & Hers Health has a short interest ratio ("days to cover") of 5.01.

Change versus previous month

Short interest in Hims & Hers Health has recently decreased by 2.37%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hims & Hers Health does not currently pay a dividend.

Dividend Growth

Hims & Hers Health does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.10

News Sentiment

Hims & Hers Health has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 47 news articles for Hims & Hers Health this week, compared to 8 articles on an average week.

Search Interest

52 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.

MarketBeat Follows

14 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,826,977.00 in company stock.

Percentage Held by Insiders

11.76% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/31/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NYSE:HIMS
• CIK: 1773751
• Web: www.forhims.com
• Phone: 415-851-0195
• Fax: N/A
• Employees: 2,442
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Hims & Hers Health: $32.43
• High Price Target: $60.00
• Low Price Target: $23.00
• Potential Upside/Downside: +17.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $128.37 million
• Net Margins: -5.51%
• Pretax Margin: -6.35%
• Return on Equity: -6.51%
• Return on Assets: -1.20%

Debt

• Debt-to-Equity Ratio: 4.21
• Current Ratio: 0.93
• Quick Ratio: 0.87

Sales & Book Value

• Annual Sales: $2.58 billion
• Price / Sales: 2.50
• Cash Flow: $0.78 per share
• Price / Cash Flow: 35.45
• Book Value: $2.38 per share
• Price / Book: 11.59

Miscellaneous

• Outstanding Shares: 233,313,000
• Free Float: 205,875,000
• Market Cap: $6.44 billion
• Optionable: Optionable
• Beta: 2.44